<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01767597</url>
  </required_header>
  <id_info>
    <org_study_id>IMEA 38</org_study_id>
    <secondary_id>2011-A01603-38</secondary_id>
    <nct_id>NCT01767597</nct_id>
  </id_info>
  <brief_title>Application of HBV Rapid Tests as a Tool for Wide-Use Screening</brief_title>
  <acronym>OPTISCREEN-B</acronym>
  <official_title>Is the Combination of Screening Algorithms and Use of Hepatitis B Rapid Tests Useful in Optimizing the Screening and Prevention of Hepatitis B?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mairie de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BioMérieux</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      With over 280 000 chronic carriers, 2,500 new annual cases and 1,300 deaths each year,
      hepatitis B is currently a frequent and potentially severe disease in France, despite efforts
      towards prevention and effective care.

      In terms of prevention, France has very low immunization coverage (27.7%) and a high
      percentage of people ignoring HBV status (55%), leading to a delay in care. This is partly
      explained by poor knowledge of hepatitis B infection in the general population and an
      underestimation of the health impact of hepatitis B by doctors and health officials. Until
      recently, there have been no national guidelines governing its implementation (which is
      variable depending on the structures where screening is performed) and an insufficient
      evaluation of screening practices. Thus, data on the severity of liver disease, indications
      for treatment of HBV-infected patients and data on the use of vaccination for nonimmunized
      people are scarce. Furthermore, while HIV rapid tests are beginning to be used more widely,
      particularly to address the issue of people who do not come back and collect their results
      and to better adapt &quot;counselling&quot;, their usefulness to detect of hepatitis B virus has not
      been evaluated to date.

      The main objective of the Optiscreen B Study is to determine the benefit, if any, of using
      rapid tests as a screening tool to improve diagnosis, care and prevention of hepatitis B.
      Individuals risk of HBV-infection will be randomized into 2 groups, one group for which
      screening will be performed by usual serological test and a second group for which screening
      will be based on rapid tests. Centers will be selected to represent a diverse range of health
      centers whose aims include screening, prevention and/or vaccination.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients Appropriately Seeking Care</measure>
    <time_frame>6 months</time_frame>
    <description>Subjects who are considered required to seek further care are as follows:
those who need HBV vaccination (non-immunized)
those who are infected with hepatitis B virus (infected)
Of these patients, subjects who have achieved appropriate care are considered as follows:
non immunized subjects who have initiated HBV vaccination sequence (vaccinated)
infected subjects who seek health care at a specialized center, allowing to quantify the severity of liver-related disease (infected with care)
The percentage of patients appropriately seeking care will be then calculated by the following formula:
((nb Vaccinated + nb infected with care) / (nb non-immunized + nb infected))*100</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1000</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Liver Cirrhosis</condition>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>ELISA testing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HBV infection status determined by enzyme-linked immuno-assay (ELISA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rapid testing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HBV infection status determined initially by a rapid test, then confirmed by enzyme-linked immuno-assay (ELISA).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ELISA testing</intervention_name>
    <description>Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg) and anti-HBsAg antibody (anti-HBs Ab) status. Results will be given after test results are available (8-10 days).</description>
    <arm_group_label>ELISA testing</arm_group_label>
    <arm_group_label>Rapid testing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Rapid testing</intervention_name>
    <description>A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®) and anti-HBs antibody status (anti-HBs Ab, using Quick ProfileTM). Results will be given the same day.</description>
    <arm_group_label>Rapid testing</arm_group_label>
    <other_name>VIKIA®, Biomerieux, Marcy-l'Étoile, France</other_name>
    <other_name>Quick ProfileTM, Lumiquick, Santa Clara, CA, USA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Born in a country of middle or high HBV endemicity

          -  Parents born in a country of middle or high HBV endemicity

          -  Travellers or residents from a country of middle or high HBV endemicity

          -  Blood, organ, tissue, sperm, and/or ovary donners or candidate donners.

          -  Health-care workers suspected of coming into direct contact with an HBV-infected
             individual and/or exposed to blood or any biological products from an HBV-infected
             individual

          -  Close contact with HBsAg-positive individuals (living in the same household, sexual
             partner, sharing needles, etc.)

          -  Individuals with accidental exposure to HBV

          -  Individuals with multiple sexual partners

          -  Men who have sex with men

          -  Pregnant women

          -  Hemodialysis

          -  Individuals requiring immunosuppressive therapy

          -  Individuals with persistently elevated transaminase levels

          -  HIV-positive

          -  Intravenous drug users

        Exclusion Criteria:

          -  Age &lt;18 years old

          -  Not capable of providing informed consent

          -  Already participated in a multi-center validation of HBV rapid tests

          -  Having, in their possession, irrefutable results of a prior test for hepatitis B virus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie Bottero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Saint-Antoine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de Santé au Maire-Volta</name>
      <address>
        <city>Paris</city>
        <zip>75003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'examen de santé de la CPAM, antenne rue du Maroc</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultation Policlinique de l'hôpital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultation Voyage de l'hôpital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CDAG de Belleville</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.optiscreenb.fr/</url>
    <description>OPTISCREEN B study website</description>
  </link>
  <results_reference>
    <citation>Bottero J, Boyd A, Gozlan J, Carrat F, Lemoine M, Rougier H, Varsat B, Boo N, Charlois-Ou C, Collignon A, Cha O, Campa P, Dhotte P, Girard PM, Lacombe K. Effectiveness of hepatitis B rapid tests toward linkage-to-care: results of a randomized, multicenter study. Eur J Gastroenterol Hepatol. 2016 Jun;28(6):633-9. doi: 10.1097/MEG.0000000000000620.</citation>
    <PMID>26954517</PMID>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2013</study_first_submitted>
  <study_first_submitted_qc>January 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2013</study_first_posted>
  <results_first_submitted>August 26, 2016</results_first_submitted>
  <results_first_submitted_qc>October 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 13, 2016</results_first_posted>
  <last_update_submitted>October 21, 2016</last_update_submitted>
  <last_update_submitted_qc>October 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rapid test</keyword>
  <keyword>screening</keyword>
  <keyword>ELISA</keyword>
  <keyword>hepatitis B virus</keyword>
  <keyword>access to care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared upon official request by interested parties. All requests are subject to approval by the Scientific Committee.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From 29 February 2012 to 5 July 2012, volunteers were recruited from five study centers in the Paris metropolitan region, which actively participate in HBV screening, vaccination, and care – two sexually transmitted disease clinics, one primary healthcare center, one general screening center, and one travel clinic.</recruitment_details>
      <pre_assignment_details>2061 participants were initially screened for eligibility. Of them, 625 did not meet inclusion criteria and 436 declined to participate. In total, 1000 participants were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ELISA Testing</title>
          <description>HBV infection status determined by enzyme-linked immuno-assay (ELISA)
ELISA testing: Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg) and anti-HBsAg antibody (anti-HBs Ab) status. Results will be given after test results are available (8-10 days).</description>
        </group>
        <group group_id="P2">
          <title>Rapid Testing</title>
          <description>HBV infection status determined initially by a rapid test, then confirmed by enzyme-linked immuno-assay (ELISA).
ELISA testing: Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg) and anti-HBsAg antibody (anti-HBs Ab) status. Results will be given after test results are available (8-10 days).
Rapid testing: A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®) and anti-HBs antibody status (anti-HBs Ab, using Quick ProfileTM). Results will be given the same day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="500"/>
                <participants group_id="P2" count="500"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="496"/>
                <participants group_id="P2" count="499"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Incomplete intervention</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants completing their intervention.</population>
      <group_list>
        <group group_id="B1">
          <title>ELISA Testing</title>
          <description>HBV infection status determined by enzyme-linked immuno-assay (ELISA)
ELISA testing: Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg) and anti-HBsAg antibody (anti-HBs Ab) status. Results will be given after test results are available (8-10 days).</description>
        </group>
        <group group_id="B2">
          <title>Rapid Testing</title>
          <description>HBV infection status determined initially by a rapid test, then confirmed by enzyme-linked immuno-assay (ELISA).
ELISA testing: Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg) and anti-HBsAg antibody (anti-HBs Ab) status. Results will be given after test results are available (8-10 days).
Rapid testing: A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®) and anti-HBs antibody status (anti-HBs Ab, using Quick ProfileTM). Results will be given the same day.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="496"/>
            <count group_id="B2" value="499"/>
            <count group_id="B3" value="995"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.7" spread="16.0"/>
                    <measurement group_id="B2" value="40.1" spread="15.6"/>
                    <measurement group_id="B3" value="40.4" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="250"/>
                    <measurement group_id="B2" value="272"/>
                    <measurement group_id="B3" value="522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="246"/>
                    <measurement group_id="B2" value="227"/>
                    <measurement group_id="B3" value="473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HBV prevalence of birth country</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Low (&lt;2.0%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="292"/>
                    <measurement group_id="B2" value="275"/>
                    <measurement group_id="B3" value="567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate (2.0–8.0%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High (&gt;8.0%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Health insurance plan</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Social security</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="465"/>
                    <measurement group_id="B2" value="472"/>
                    <measurement group_id="B3" value="937"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CMU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Appropriately Seeking Care</title>
        <description>Subjects who are considered required to seek further care are as follows:
those who need HBV vaccination (non-immunized)
those who are infected with hepatitis B virus (infected)
Of these patients, subjects who have achieved appropriate care are considered as follows:
non immunized subjects who have initiated HBV vaccination sequence (vaccinated)
infected subjects who seek health care at a specialized center, allowing to quantify the severity of liver-related disease (infected with care)
The percentage of patients appropriately seeking care will be then calculated by the following formula:
((nb Vaccinated + nb infected with care) / (nb non-immunized + nb infected))*100</description>
        <time_frame>6 months</time_frame>
        <population>Only participants needing further medical intervention were included in analysis: non-immunized (HBsAg negative, anti-HBc antibody negative, anti-HBs antibody negative) or infected (HBsAg positive).</population>
        <group_list>
          <group group_id="O1">
            <title>ELISA Testing</title>
            <description>HBV infection status determined by enzyme-linked immuno-assay (ELISA)
ELISA testing: Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg) and anti-HBsAg antibody (anti-HBs Ab) status. Results will be given after test results are available (8-10 days).</description>
          </group>
          <group group_id="O2">
            <title>Rapid Testing</title>
            <description>HBV infection status determined initially by a rapid test, then confirmed by enzyme-linked immuno-assay (ELISA).
ELISA testing: Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg) and anti-HBsAg antibody (anti-HBs Ab) status. Results will be given after test results are available (8-10 days).
Rapid testing: A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®) and anti-HBs antibody status (anti-HBs Ab, using Quick ProfileTM). Results will be given the same day.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Appropriately Seeking Care</title>
          <description>Subjects who are considered required to seek further care are as follows:
those who need HBV vaccination (non-immunized)
those who are infected with hepatitis B virus (infected)
Of these patients, subjects who have achieved appropriate care are considered as follows:
non immunized subjects who have initiated HBV vaccination sequence (vaccinated)
infected subjects who seek health care at a specialized center, allowing to quantify the severity of liver-related disease (infected with care)
The percentage of patients appropriately seeking care will be then calculated by the following formula:
((nb Vaccinated + nb infected with care) / (nb non-immunized + nb infected))*100</description>
          <population>Only participants needing further medical intervention were included in analysis: non-immunized (HBsAg negative, anti-HBc antibody negative, anti-HBs antibody negative) or infected (HBsAg positive).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7"/>
                    <measurement group_id="O2" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Power calculations were performed to detect &gt;15% difference in immediate linkage-to-care and vaccination. We hypothesized from discussions with an expert panel that ~30% of participants would have appropriate care with standard HBV serology. Assuming type 1 error=0.05 and power=80%, 152 participants per arm would be needed. As ~40% of the population would be nonimmunized or HBsAg-positive from previous data, a minimum 375 participants per arm would be required.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5</p_value>
            <p_value_desc>No p-value adjustments for multiple comparisons were required. Significance was determined using a p-value &lt;0.05.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>Any event possibly related to physical HBV test.</desc>
      <group_list>
        <group group_id="E1">
          <title>ELISA Testing</title>
          <description>HBV infection status determined by enzyme-linked immuno-assay (ELISA)
ELISA testing: Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg) and anti-HBsAg antibody (anti-HBs Ab) status. Results will be given after test results are available (8-10 days).</description>
        </group>
        <group group_id="E2">
          <title>Rapid Testing</title>
          <description>HBV infection status determined initially by a rapid test, then confirmed by enzyme-linked immuno-assay (ELISA).
ELISA testing: Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg) and anti-HBsAg antibody (anti-HBs Ab) status. Results will be given after test results are available (8-10 days).
Rapid testing: A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®) and anti-HBs antibody status (anti-HBs Ab, using Quick ProfileTM). Results will be given the same day.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="499"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Low prevalence of HBV infection; individuals with barriers to healthcare were underrepresented; Quick Profile anti-HBsAb rapid test unable to confirm nonimmunized status; intervention had same-day blood draws, which is not done in routine practice.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Julie Bottero</name_or_title>
      <organization>Service des maladies infectieuses et tropicales - Hôpital Saint-Antoine</organization>
      <phone>+33 1 49 28 04 24</phone>
      <email>julie.bottero@aphp.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

